Trilo Therapeutics is developing best-in-class peptide-drug conjugates that address the dose-limiting toxicity of current generation ADCs.
Trilo Therapeutics has raised $1.7M in total funding. The most recent round was Seed. The last funding was announced in December 2022.
Trilo Therapeutics's investors include National Science Foundation.
Trilo Therapeutics is headquartered in San Francisco, United States.
Trilo Therapeutics is developing best-in-class peptide-drug conjugates that address the dose-limiting toxicity of current generation ADCs.
Trilo Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Trilo Therapeutics — Funding & Investors." VCBacked, December 1, 2022, https://www.vcbacked.co/company/trilo-therapeutics. Accessed August 14, 2026.
VCBacked. (2022). Trilo Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/trilo-therapeutics
{{cite web |title=Trilo Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/trilo-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated